XtalPi Stock

xtalpi.comHealthcare / BioTech & PharmaFounded: 2016

XtalPi is a pharmaceutical technology company focused on reinventing the industry's approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform.

Register To Buy and Sell Shares

For more details on financing and valuation for XtalPi, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access XtalPi’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like XtalPi.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Frequently Asked Questions About XtalPi’s Stock

plusminus
Can you buy XtalPi’s stock?
XtalPi is not publicly traded on NYSE or NASDAQ in the U.S. To buy XtalPi’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell XtalPi’s stock?
Yes, you can sell stock of a private company like XtalPi. Forge can help you sell your XtalPi stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is XtalPi’s stock price?
XtalPi is a privately held company and therefore does not have a public stock price. However, you may access XtalPi’s private market stock price with Forge Data.
plusminus
What is XtalPi’s stock ticker symbol?
XtalPi does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

XtalPi to collaborate with Eli Lilly on using AI and robotics in drug discovery · TechNode
Pharmaceutical technology company XtalPi has announced a collaboration with US drug maker Eli Lilly. The partnership will focus on using AI and robotics in drug discovery, with an upfront payment of up to $250 million. XtalPi will use its ID4Inno™ small-molecule drug discovery platform, combining AI, autonomous labs, and expert domain knowledge for efficient drug discovery processes.
XtalPi announces $250m AI drug discovery collaboration with Eli Lilly
XtalPi has entered into a $250m partnership with Eli Lilly to utilise artificial intelligence (AI) for drug discovery. The collaboration will leverage XtalPi’s integrated AI capabilities and robotics platform to design and deliver drug candidates. The AI drug discovery solution will be used to create a novel compound, which will be advanced by Lilly through clinical and commercial development.
Chinese pharma firm uses AI to find new industrial materials
XtalPi, a pharmaceutical firm backed by Tencent and Softbank, plans to leverage AI to expand into materials science and discover new industrial materials. The company also intends to significantly expand its facilities in Shanghai and Hong Kong, but has no immediate plans for an IPO.
Updated on: Apr 14, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.